BML-210

BML-210 is a potent HDAC inhibitor. BML-210 can inhibit the HDAC4-VP16-driven reporter signal with an apparent IC50 of ∼5 µM. BML-210 has a specific disruptive effect on the HDAC4:MEF2 interaction. BML-210 causes an increase in the G0/G1 phase. BML-210 induces apoptosis and displays antitumour activities in orthotopic mammary tumours in mice[1][2][3].

Product Specifications

CAS Number

[537034-17-6]

UNSPSC

12352005

Hazard Statement

H302, H361, H372, H410

Target

Apoptosis; HDAC

Type

Reference compound

Related Pathways

Apoptosis; Cell Cycle/DNA Damage; Epigenetics

Applications

Cancer-programmed cell death

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/BML-210.html

Concentration

10mM

Purity

98.04

Solubility

DMSO : ≥ 30 mg/mL

Smiles

O=C(NC1=CC=CC=C1N)CCCCCCC(NC2=CC=CC=C2)=O

Molecular Formula

C20H25N3O2

Molecular Weight

339.43

Precautions

H302, H361, H372, H410

References & Citations

[1]Nimanthi Jayathilaka, et al. Inhibition of the function of class IIa HDACs by blocking their interaction with MEF2. Nucleic Acids Res. 2012 Jul; 40 (12) : 5378–5388.|[2]Veronika Borutinskaite, et al. The Histone Deacetylase Inhibitor BML-210 Influences Gene and Protein Expression in Human Promyelocytic Leukemia NB4 Cells via Epigenetic Reprogramming. Int J Mol Sci. 2015 Aug; 16 (8) : 18252–18269.|[3]Zhuolong Zhou, et al. An organoid-based screen for epigenetic inhibitors that stimulate antigen presentation and potentiate T-cell-mediated cytotoxicity. Nat Biomed Eng. 2021 Nov;5 (11) :1320-1335.